RxDoctor Payments DataLook up a doctor →

Philip Green, MD

Interventional Cardiology · New York, NYNPI 1275675027

Payments from drug & device makers

$213,536in general payments, 2019–2025

Across 521 payments — averaging $409.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$78K
  • Heartflow, Inc.$29K
  • Medtronic$26K
  • Pfizer$17K
  • Boston Scientific$17K
  • AstraZeneca$13K
  • plus $33K from 36 others

What the payments were for

  • Consulting fees$9,16010%
  • Speaking & faculty fees$51,80055%
  • Travel & lodging$10,79011%
  • Food & beverage$21,98823%
  • Education$170%
  • Gifts$320%
  • Entertainment$1480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$213,536 in reported general payments places this provider in the 85th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$1,193,594
Medicare patients
648
Services billed
3,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$128,092
Repatha SureclickEvolocumab138$94,710
OzempicSemaglutide52$86,308
XareltoRivaroxaban81$83,738
JardianceEmpagliflozin43$63,903
BrilintaTicagrelor49$43,913
FarxigaDapagliflozin Propanediol27$31,823
JanuviaSitagliptin Phosphate26$21,886
InpefaSotagliflozin30$20,711
Repatha PushtronexEvolocumab22$16,514
NexletolBempedoic Acid28$15,454
TradjentaLinagliptin11$11,299
Atorvastatin Calcium689$9,023
Metoprolol Succinate492$8,702
Praluent PenAlirocumab14$8,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17,163$128,092138 claims
Johnson & JohnsonXarelto$38$83,73881 claims
AstraZenecaBrilinta, Farxiga$13,491$75,73576 claims
Boehringer IngelheimJardiance, Tradjenta$210$75,20154 claims
Lexicon Pharmaceuticals, Inc.Inpefa$19$20,71130 claims
Esperion Therapeutics, Inc.Nexletol$56$15,45428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →